Teva Pharmaceutical Industries (NYSE:TEVA) Rating Increased to Strong-Buy at Wall Street Zen

Teva Pharmaceutical Industries (NYSE:TEVA) was upgraded by stock analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research note issued on Saturday.

Several other research analysts also recently issued reports on the stock. JPMorgan Chase & Co. upped their price target on shares of Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 16th. Scotiabank boosted their target price on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock a “sector outperform” rating in a research note on Thursday. Jefferies Financial Group increased their price target on shares of Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday, January 6th. Truist Financial raised their price target on shares of Teva Pharmaceutical Industries from $36.00 to $38.00 and gave the company a “buy” rating in a report on Thursday. Finally, Piper Sandler upped their price objective on Teva Pharmaceutical Industries from $30.00 to $40.00 and gave the stock an “overweight” rating in a report on Monday, December 22nd. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Teva Pharmaceutical Industries presently has an average rating of “Moderate Buy” and a consensus price target of $36.00.

Teva Pharmaceutical Industries Stock Up 3.1%

NYSE TEVA opened at $34.08 on Friday. The stock’s 50 day simple moving average is $30.49 and its 200 day simple moving average is $23.15. Teva Pharmaceutical Industries has a one year low of $12.47 and a one year high of $34.11. The firm has a market cap of $39.09 billion, a PE ratio of 28.40, a price-to-earnings-growth ratio of 1.88 and a beta of 0.66. The company has a debt-to-equity ratio of 2.31, a current ratio of 1.11 and a quick ratio of 0.82.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Wednesday, January 28th. The company reported $0.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.31. The firm had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.36 billion. Teva Pharmaceutical Industries had a return on equity of 48.20% and a net margin of 8.16%.The business’s revenue for the quarter was up 11.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.71 EPS. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. As a group, sell-side analysts forecast that Teva Pharmaceutical Industries will post 2.5 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Mark Sabag sold 216,892 shares of the company’s stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $28.73, for a total value of $6,231,307.16. Following the completion of the sale, the insider owned 52,828 shares in the company, valued at approximately $1,517,748.44. This represents a 80.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CAO Amir Weiss sold 12,300 shares of the firm’s stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $30.20, for a total value of $371,460.00. Following the transaction, the chief accounting officer owned 5,650 shares in the company, valued at approximately $170,630. This trade represents a 68.52% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 622,060 shares of company stock worth $17,076,965. Company insiders own 0.49% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of TEVA. Grove Bank & Trust increased its stake in Teva Pharmaceutical Industries by 300.0% in the fourth quarter. Grove Bank & Trust now owns 1,000 shares of the company’s stock valued at $31,000 after purchasing an additional 750 shares in the last quarter. Advisors Asset Management Inc. acquired a new position in shares of Teva Pharmaceutical Industries in the 2nd quarter valued at $41,000. Cromwell Holdings LLC grew its holdings in shares of Teva Pharmaceutical Industries by 40.3% in the 3rd quarter. Cromwell Holdings LLC now owns 2,191 shares of the company’s stock valued at $44,000 after buying an additional 629 shares during the period. MAI Capital Management increased its position in shares of Teva Pharmaceutical Industries by 26.8% in the 2nd quarter. MAI Capital Management now owns 3,293 shares of the company’s stock valued at $55,000 after buying an additional 697 shares in the last quarter. Finally, Rothschild Investment LLC raised its stake in Teva Pharmaceutical Industries by 97.0% during the 3rd quarter. Rothschild Investment LLC now owns 2,738 shares of the company’s stock worth $55,000 after buying an additional 1,348 shares during the period. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries News Summary

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Q4 fundamentals beat expectations — Teva reported stronger-than-expected results (reported EPS and revenue outperformed consensus), revenue grew year-over-year driven by a Sanofi milestone and Austedo growth, and management set FY‑2026 EPS guidance of roughly 2.57–2.77, supporting a higher valuation. TEVA’s Q4 Earnings Beat, Branded Drugs Drive Revenue Growth
• Positive Sentiment: Barclays raised its price target to $38 and set an “overweight” rating, signaling upside from current levels and lending third‑party validation to the stock’s outlook. Barclays raises TEVA price target to $38
• Positive Sentiment: Truist increased its price target to $38 with a “buy” rating, reinforcing bullish analyst sentiment following the quarter. Truist raises TEVA price target to $38
• Positive Sentiment: Scotiabank lifted its target to $40 and moved to “sector outperform,” the highest target among recent broker notes, which may attract more investor interest. Scotiabank raises TEVA price target to $40

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.